Basic Information



GTO ID GTC4008
Trial ID NCT06080984
Disease Head and Neck Squamous Cell Carcinoma | Melanoma | Sarcoma
Altered gene E1A|E1B
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment SDJ001;YD06-1
PhasePhase1
Recruitment statusRecruiting
TitleThe Application of Novel Oncolytic Virus in Late Stage Solid Tumors
Year2023
CountryChina
Company sponsorWest China Hospital
Other ID(s)2023-833
Vector information
Vectoradenovirus
Additional featureGM-CSF

Clinical Result

Cohort1: SDJ001_dose level 1_HNSCC
Administration route intratumoral injection
Dosage 5E11 pfu, on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects
Age Adult, Older_Adult
Cohort2: SDJ001_dose level 2_HNSCC
Administration route intratumoral injection
Dosage 1E12 pfu, on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects
Age Adult, Older_Adult
Cohort3: YD06-1_Melanoma
Administration route intratumoral injection
Dosage 1E6~E8 pfu/ml
Age Adult, Older_Adult
Cohort4: YD06-1_Sarcoma
Administration route intratumoral injection
Dosage 1E6~E8 pfu/ml
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph